Overview of the development and current use of CRM197 conjugate vaccines for pediatric use

Vaccine

Volumn 28, Issue 27, 2010, Pages 4335-4339

  Shinefield, Henry R ^a  

^a NONE   (United States)

Author keywords

Conjugate vaccines; CRM197; Pediatric vaccines

Indexed keywords

BACTERIAL VACCINE; CARRIER PROTEIN; DIPHTHERIA TOXOID CRM197; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOLOGICAL ADJUVANT; MENINGOCOCCUS B VACCINE; MENINGOCOCCUS VACCINE; MSV 4; PENICILLIN G; PNEUMOCOCCUS VACCINE; PREVNAR 13; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INDIGENOUS PEOPLE; INFLUENZA B; MENINGOCOCCOSIS; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SEROTYPE; VACCINE PRODUCTION;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; VACCINES, CONJUGATE;

EID: 77952743680     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.072     Document Type: Review

References (51)

1. Schneerson R., Barrera O., Sutton A., and Robbins J.B. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 152 (1980) 361-376
2. Beuvery E.C., Miedema F., van Delft R.W., Haverkamp J., Tiesjema R.H., and Nagel J. Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate. J Infect 6 3 (1983) 247-255
3. 197. Appl Environ Microbiol 46 3 (1983) 560-564
4. Black S.B., and Shinefield H.R. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis 11 8 (1992) 610-613
5. 197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatr Infect Dis J 14 11 (1995) 978-981
6. Decker M.D., Edwards K.M., Bradley R., and Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 120 2 Pt 1 (1992) 184-189
7. Prevnar 13 [package insert] (2010), Wyeth Pharmaceuticals, Philadelphia, PA
8. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
9. Black S., France E.K., Isaacman D., Bracken L., Lewis E., Hansen J., et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 26 9 (2007) 771-777
10. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., and Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49 2 (2009) 205-212
11. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54 (2005) 893-897
12. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 57 (2008) 144-148
13. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 9431 (2004) 365-367
14. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 6 (1999) 1569-1572
15. Maiden M.C.J., Ibarz-Pavón A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197 (2008) 737-743
16. Maiden M.C.J., Stuart J.M., and The UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 (2002) 1829-1830
17. Perrett K.P., Snape M.D., Ford K.J., John T.M., Yu L.M., Langley J.M., et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 28 3 (2009) 186-193
18. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299 2 (2008) 173-184
19. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 54 RR-7 (2005) 1-21
20. Shepard C.W., Ortega-Sanchez I.R., Scott 2d R.D., Rosenstein NE, and ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115 (2005) 1220-1232
21. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 50 (2010) 184-191
22. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 5 (1998) 2093-2098
23. 197 conjugate vaccine. Vaccine 26 (2008) 4602-4607
24. Buttery J.P., Riddell A., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 298 14 (2005) 1751-1758
25. Kaplan S.L., Mason Jr. E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113 3 Pt 1 (2004) 443-449
26. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., and Finelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 3 (2005) e408-e413
27. Messina A., Katz-Gaynor K., Barton T., Ahmad N., Ghaffrar F., Rasko D., et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 26 6 (2007) 461-467
28. Casteñada E., Agudelo C.I., Regueira M., Corso A., de Cunto Brandileone M.C., and Brandão A.P. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 28 9 (2009) e265-e270
29. Pelton S.I., Loughlin A.M., and Marchant C.D. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities; changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 23 11 (2004) 1015-1022
30. Dagan R. Serotype replacement in perspective. Vaccine 27 Suppl. 3 (2009) C22-C24
31. Black S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J 29 (2010) 301-303
32. Shouval D., Greenberg D., Givon-Lavi N., Porat N., and Dagan R. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J 28 4 (2009) 277-282
33. Menzies R., Turnour C., Chiu C., and McIntyre P. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Commun Dis Intell 32 Suppl (2008) S2-67
34. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 17-18 (2005) 2191-2196
35. Wilson N., Baker M., Martin D., Lennon D., O'Hallahan J., Jones N., et al. Meningococcal disease epidemiology and control in New Zealand. N Z Med J 108 1010 (1995) 437-442
36. Martin D.R., Walker S.J., Baker M.G., and Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 177 2 (1998) 497-500
37. McNicholas A., Galloway Y., Martin D., Sexton K., and O'Hallahan J. Surveillance of vaccine breakthrough cases following MeNZB vaccination. N Z Med J 121 1272 (2008) 38-46
38. Lacapa R., Bliss S.J., Larzelere-Hinton F., Eagle K.J., McGinty D.J., and Parkinson A.J. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 47 4 (2008) 476-484
39. Bliss S.J., Larzalere-Hinton F., Lacapa R., Eagle K.R., Frizzell F., Parkinson A., et al. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005. Arch Intern Med 168 7 (2008) 749-755
40. Millar E.V., O'Brien K.L., Levine O.S., Kvamme S., Reid R., and Santosham M. Toward elimination of Haemophilus influenzae type B carriage and disease among high-risk American Indian children. Am J Public Health 90 (2000) 1550-1554
41. Singleton R., Hammitt L., Hennessy T., Bulkow L., DeByle C., Parkinson A., et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 118 2 (2006) e421-e429
42. Roche P., Krause V., Andrews R., Carter L., Coleman D., Cook H., et al. Invasive pneumococcal disease in Australia, 2002. Invasive pneumococcal disease in Australia, 2002. Commun Dis Intell 27 4 (2003) 466-467
43. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 362 9381 (2003) 355-361
44. Millar E.V., O'Brien K.L., Watt J.P., Bronsdon M.A., Dallas J., Whitney C.G., et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 43 1 (2006) 8-15
45. Madhi S.A., Kuwanda L., Saarinen L., Cutland C., Mothupi R., Kayhty H., et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 23 48-49 (2005) 5517-5525
46. Madhi S.A., Klugman K.P., Kuwanda L., Cutland C., Käythy H., and Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 199 8 (2009) 1168-1176
47. Barton M., Wasfy S., Dipchand A.I., Hébert D., Ng V., Solomon M., et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 28 8 (2009) 688-692
48. Brynjolfsson S.F., Bjarnarson S.P., Mori E., Del Giudice G., and Jonsdottir I. Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006. Vaccine 26 35 (2008) 4557-4562
49. Baudner B.C., Morandi M., Giuliani M.M., Verhoef J.C., Junginger H.E., Costantino P., et al. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J Infect Dis 189 5 (2004) 828-832
50. von Hunolstein C., Teloni R., Mariotti S., Recchia S., Orefici G., and Nisini R. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine. Int Immunol 12 3 (2000) 295-303
51. Dicko M., Oni A.Q.O., Ganivet S., Kone S., Pierre L., and Jacquet B. Safety of immunization injections in Africa: not simply a problem of logistics. Bull World Health Org 78 2 (2000) 163-169